Every material Form 8-K Freshpet filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Freshpet's Compensation Committee approved a retention equity grant to Chief Operating Officer Nicola Baty, effective December 8, 2025, citing a substantial drop in the value of her earlier inducement awards. The grant's performance-based portion depends on three-year net sales and Adjusted EBITDA margin goals, so it adds potential future share dilution tied to company results.
Grant date value of $1,750,819.72 in restricted stock units, effective December 8, 2025
13,858 time-based RSUs and 13,858 performance-based RSUs
Time-based RSUs vest in two equal annual installments beginning January 3, 2027
Performance RSUs tied 50% to FY 2025-2027 cumulative net sales and 50% to three-year Adjusted EBITDA margin goals
Freshpet reported third-quarter 2025 net sales of $288.8 million, up 14.0% from a year earlier, and net income of $101.7 million, which includes a $77.9 million tax benefit from releasing a valuation allowance. The company narrowed its full-year 2025 net sales growth outlook to about 13% and cut its Adjusted EBITDA range to $190 million to $195 million from $190 million to $210 million, while lowering its capital expenditure plan to about $140 million from about $175 million. Shareholders get higher sales but a lower top end for profit guidance, and the reported net income gain depends on a one-time tax item.
Q3 net sales rose 14.0% to $288.8 million; Q3 Adjusted EBITDA was $54.6 million versus $43.5 million a year earlier
Q3 net income of $101.7 million includes a discrete $77.9 million tax benefit; Q3 gross margin was 39.5% versus 40.4%
2025 Adjusted EBITDA guidance is $190 million to $195 million, versus $190 million to $210 million previously
2025 capital expenditure guidance is about $140 million, down from about $175 million; the company expects to be free cash flow positive for 2025
Freshpet said Chief Financial Officer Todd Cunfer will resign effective October 17, 2025, to accept another position. The board named Vice President-Finance Ivan Garcia as interim CFO on the same date, and the company will search for a permanent replacement.
Todd Cunfer informed the company on October 3, 2025 of his resignation as CFO, effective October 17, 2025.
Ivan Garcia, 41, has served as Vice President-Finance since July 2023 and joined Freshpet in February 2014.
Garcia's annual salary rises to $341,214, with a 40% target bonus and a 25% long-term incentive target, prorated for the partial year.
Garcia received 3,000 restricted stock units vesting on the first anniversary of the grant date.
Freshpet reported second-quarter 2025 net sales of $264.7 million, up 12.5%, and net income of $16.4 million, compared with a net loss of $1.7 million a year earlier. The company lowered its 2025 net sales growth forecast to 13% to 16% from 15% to 18%, cut its capital expenditure forecast to about $175 million from about $225 million, and removed its $1.8 billion 2027 net sales target, which matters to shareholders because it reduces the company's stated growth expectations.
Q2 2025 net sales were $264.7 million, up 12.5% from $235.3 million, with volume gains of 10.8%.
Q2 2025 net income was $16.4 million, or $0.33 per diluted share, versus a net loss of $1.7 million in the prior year period.
2025 net sales growth guidance was cut to 13% to 16%, from 15% to 18%; Adjusted EBITDA guidance of $190 million to $210 million was unchanged.
Capital expenditure guidance for 2025 was cut to about $175 million from about $225 million, and the 2027 net sales target of $1.8 billion was removed.
Freshpet reported first-quarter 2025 net sales of $263.2 million, up 17.6% from a year earlier, but posted a net loss of $12.7 million compared with net income of $18.6 million in the prior-year quarter. The company cut its full-year 2025 net sales and Adjusted EBITDA guidance and lowered its capital expenditure forecast, which bears on shareholders' expectations for growth and profit this year.
Net sales were $263.2 million, up from $223.8 million, driven by volume gains of 14.9%.
Net loss was $12.7 million, or $(0.26) per diluted share, versus net income of $18.6 million, or $0.37 per diluted share, a year earlier; SG&A included $16.9 million of non-recurring charges.
2025 net sales outlook was lowered to $1.12 billion to $1.15 billion from $1.18 billion to $1.21 billion.
2025 Adjusted EBITDA outlook is $190 million to $210 million, versus at least $210 million previously; capital expenditures are now about $225 million, down from about $250 million.
Freshpet reported fourth-quarter and full-year 2024 results, with net sales up 22.0% in the quarter and 27.2% for the year, and full-year net income of $46.9 million compared with a net loss of $33.6 million in 2023. The company guided 2025 net sales of $1.18 billion to $1.21 billion and Adjusted EBITDA of at least $210 million, and raised its 2027 Adjusted Gross Margin and Adjusted EBITDA margin targets.
Q4 2024 net sales were $262.7 million, up 22.0%, and net income was $18.1 million versus $15.3 million a year earlier.
Full-year 2024 Adjusted EBITDA was $161.8 million, compared with $66.6 million in 2023.
2025 guidance: net sales of $1.18 billion to $1.21 billion (up 21% to 24%) and Adjusted EBITDA of at least $210 million.
2027 targets: Adjusted Gross Margin raised to 48% from 45%, and Adjusted EBITDA margin raised to 22% from 18%; net sales target of $1.8 billion unchanged.
Freshpet's compensation committee approved retention restricted stock unit (RSU) grants to CEO Billy Cyr, President and Co-Founder Scott Morris, and Chief Human Resources Officer Thembeka Machaba, effective January 3, 2025. The grants combine time-based vesting with performance-based awards tied to three-year fiscal 2025-2027 net sales and Adjusted EBITDA margin goals, and the company said the awards are intended to retain these executives.
Grant date value: $8 million for Cyr, $4 million for Morris, and $2,043,750 for Machaba
Time-based RSUs vest one-third on each of the first, second and third anniversaries of the January 3, 2025 grant date, subject to continued employment
Performance-based RSUs vest based 50% on cumulative net sales and 50% on Adjusted EBITDA margin for FY 2025-2027, with 80% to 120% of target possible
Full award agreements will be filed with the company's next Form 10-Q
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Freshpet filing is on SEC EDGAR ↗. 8-K briefs of other companies →